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Abstract
Introduction: Critical illness polyneuromyopathy (CIPNM) is a common complication of critical illness presenting with 
muscle weakness and is associated with increased duration of mechanical ventilation and weaning period. No 
preventive tool and no specific treatment have been proposed so far for CIPNM. Electrical muscle stimulation (EMS) has 
been shown to be beneficial in patients with severe chronic heart failure and chronic obstructive pulmonary disease. 
Aim of our study was to assess the efficacy of EMS in preventing CIPNM in critically ill patients.
Methods: One hundred and forty consecutive critically ill patients with an APACHE II score ≥ 13 were randomly 
assigned after stratification to the EMS group (n = 68) (age:61 ± 19 years) (APACHE II:18 ± 4, SOFA:9 ± 3) or to the control 
group (n = 72) (age:58 ± 18 years) (APACHE II:18 ± 5, SOFA:9 ± 3). Patients of the EMS group received daily EMS sessions. 
CIPNM was diagnosed clinically with the medical research council (MRC) scale for muscle strength (maximum score 60, 
<48/60 cut off for diagnosis) by two unblinded independent investigators. Duration of weaning from mechanical 
ventilation and intensive care unit (ICU) stay were recorded.
Results: Fifty two patients could be finally evaluated with MRC; 24 in the EMS group and 28 in the control group. 
CIPNM was diagnosed in 3 patients in the EMS group as compared to 11 patients in the control group (OR = 0.22; CI: 
0.05 to 0.92, P = 0.04). The MRC score was significantly higher in patients of the EMS group as compared to the control 
group [58 (33 to 60) vs. 52 (2 to 60) respectively, median (range), P = 0.04). The weaning period was statistically 
significantly shorter in patients of the EMS group vs. the control group [1 (0 to 10) days vs. 3 (0 to 44) days, respectively, 
median (range), P = 0.003].
Conclusions: This study suggests that daily EMS sessions prevent the development of CIPNM in critically ill patients 
and also result in shorter duration of weaning. Further studies should evaluate which patients benefit more from EMS 
and explore the EMS characteristics most appropriate for preventing CIPNM.
Trial Registration Number: ClinicalTrials.gov NCT00882830
Introduction
Critical illness polyneuromyopathy (CIPNM) is an
acquired neuromuscular disorder observed in survivors
of acute critical illness. It is characterized by profound
muscle weakness and diminished or absent deep tendon
reflexes [1] and is associated with delayed weaning from
mechanical ventilation [2] suggesting a possible relation
between limb and respiratory neuromuscular involve-
ment. In addition, the syndrome is associated with pro-
longed hospitalization and increased mortality [3]. The
diagnosis of CIPNM requires a reliable bedside muscle
strength examination and depends on patient's coopera-
tion and maximal effort [4].
Several risk factors have been identified including sys-
temic inflammatory response and sepsis [5], medications
such as corticosteroids [6] and neuromuscular blocking
agents [7], inadequate glycemic control [8], protracted
immobility [4], hypoalbuminemia [9], Gram-negative
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bacteremia [9] and severity of organ dysfunction [10].
Thus, looking for the potentially reversible risk factors
and subsequent adjustment of therapy are so far advo-
cated as preventive measures to decrease the risk of
CIPNM.
Electrical muscle stimulation (EMS) has been used as
an alternative to active exercise in patients with chronic
heart failure (CHF) [11] and chronic obstructive pulmo-
nary disease (COPD) [12,13]. Many of these patients,
even those who are clinically stable, experience severe
dyspnea on exertion, which can prohibit the regular
application of conventional exercise training, considered
necessary for an integrated therapeutic approach. In a
recent systematic review, EMS implementation in most of
the selected controlled clinical trials produced significant
improvements in muscle strength, exercise capacity and
disease-specific health status [14]. Recently, we identified
an acute systemic effect exerted by EMS on peripheral
microcirculation of critically ill patients [15]. Specifically,
after performing a 45-minute session of EMS on the
lower extremities, an improvement in the microcircula-
tion of the thenar muscle as assessed by near infrared
spectroscopy technique was observed.
Therefore, we hypothesized that EMS could benefi-
cially affect muscle functional status in the critically ill.
The scope of the present study is to assess the efficacy of
EMS in preventing CIPNM in critically ill patients hospi-
talized in a multidisciplinary ICU. The primary endpoint
was the diagnosis of CIPNM as assessed with the Medical
Research Council (MRC) scale for muscle strength and
secondary endpoints were the duration of weaning from
mechanical ventilation and the ICU length of stay. Some
of the results of this study have been previously reported
in the form of an abstract [16].
Materials and methods
Patients
The study was approved by the Scientific Council and the
Ethics Committee of the Evangelismos Hospital, Athens,
Greece. Written informed consent was given by family
members of all the patients included in the study.
All patients consecutively admitted to the multidisci-
plinary 28-bed university ICU of Evangelismos hospital, a
1000-bed tertiary care medical center, during the study
period (September 2007 to June 2009) were prospectively
considered for inclusion in the study. Exclusion criteria
were: age under 18 years, pregnancy, obesity (body mass
index >35 kg/m2), preexisting neuromuscular disease
(e.g. myasthenia Gravis, Guillain-Barré disease), diseases
with systemic vascular involvement such as systemic
lupus erythematosus, technical obstacles that did not
allow the implementation of EMS such as bone fractures
or skin lesions (e.g. burns) and end-stage malignancy.
Patients with cardiac pacemakers were also excluded
from the study. Patients with the diagnosis of brain death
were not considered for inclusion in the study. The
Sequential Organ Failure Assessment (SOFA) [17], Acute
Physiology and Chronic Health Evaluation (APACHE) II
[18] and Simplified Acute Physiology (SAPS) III [19]
severity scores were calculated for all patients on the day
of admission. These scores have been developed for the
assessment of disease severity and have a prognostic
value in patients admitted to the ICU.
Study design and randomization
On the second day after admission (24 to 48 hours after
admission) patients with an APACHE II admission score
of 13 or more were randomized after stratification in the
intervention group (EMS group) or the control group.
Stratification was made on age (50 years or younger or
older than 50 years, which is the mean value of our ICU
patient's age) and gender (male or female). Patients were
thus distributed to one of four groups after stratification.
P a t i e n t s  w i t h  a n  o d d  n u m b e r  ( i n  e a c h  o f  t h e s e  f o u r
groups) were assigned to the EMS group and patients
with an even number were assigned to the control group.
Patients assigned to the EMS group received daily EMS
sessions of both lower extremities starting from the sec-
ond day after admission until ICU discharge. Patients in
the control group did not receive sham EMS.
Electrical muscle stimulation
EMS was implemented simultaneously on the vastus lat-
eralis, vastus medialis and peroneous longus muscles of
both lower extremities. Patients received daily sessions.
In the case of hairy skin, the skin was carefully shaven
before the application. After shaving and skin cleaning,
rectangular electrodes (90 × 50 mm) were placed on the
motor points of the vastus lateralis, vastus medialis and
peroneus longus muscles of both legs. The stimulator
(Rehab 4 Pro, CEFAR Medical AB, Malmö, Sweden)
delivered biphasic, symmetric impulses of 45 Hz, 400
μsec pulse duration, 12 seconds on (including 0.8 second
rise time and 0.8 second fall time) and 6 seconds off, at
intensities able to cause visible contractions. In case of
doubt, contraction was confirmed by palpation of the
muscles involved. The duration of the session was 55
minutes including 5 minutes for warm up and 5 minutes
for recovery. EMS sessions were continued until ICU dis-
charge.
MRC muscle strength scale
The MRC score for clinical assessment of muscle strength
was used for the diagnosis of CIPNM [2]. After interrup-
tion of sedation, patients were screened daily for awaken-
ing and comprehension until ICU discharge. MRC was
assessed on the day the patients had a level of conscious-
ness adequate to respond to at least three of the following
orders ('open/close your eyes', 'look at me', 'put out yourRoutsi et al. Critical Care 2010, 14:R74
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tongue', 'nod your head', 'raise your eyebrows') [20].
Three muscle groups in all four limbs were assessed with
the MRC scale with values ranging from 0 (quadriplegia)
to 60 (normal muscle strength). The following functions
were assessed: wrist flexion, forearm flexion, shoulder
abduction, ankle dorsiflexion, knee extension, and hip
flexion [21]. Patients with an MRC score of less than 48 of
60 were diagnosed with CIPNM. The cut-off limit of 48
for the MRC score was selected because it indicates clini-
cally significant weakness and has been used previously
for the clinical identification of ICU-acquired paresis
[2,22]. The MRC score was performed by two indepen-
dent investigators that were familiar with this technique
and no more than 24 hours elapsed between the two mea-
surements. The two investigators were unaware of each
others assessment and they provided written MRC scor-
ing for each muscle group that was assessed. The mean
value of the MRC score of the two investigators was used
for the diagnosis of CIPNM. The investigators were not
blinded as to patients' allocation.
Weaning from mechanical ventilation
The weaning period was defined as the time from the
onset of weaning trials until the day there was no need for
mechanical ventilation for the next 48 hours (short-term
weaning period). During the weaning process the patients
underwent trials of spontaneous breathing on a T-piece.
Although weaning is usually defined as successful when
there is no need for mechanical ventilation for the next 48
hours after extubation, long-term mechanically venti-
lated patients especially those with CIPNM often require
reintubation and further mechanical ventilation for more
than 48 hours after a successful short-term weaning.
Therefore, we also assessed the time from the onset of
weaning trials until the day after which there was no
more need for mechanical ventilation until ICU discharge
(long-term weaning period) [20]. Long-term weaning
success was defined as the patient's ability to sustain
spontaneous breathing until ICU discharge.
Finally, the duration of mechanical ventilation, the need
for reintubation and the number of days off the ventilator
were also recorded.
Statistical analysis
Power analysis was performed prior to the study initia-
tion. We calculated that to provide 80% power with a P
value of less than 0.05 judged to be significant, a sample
size of 44 patients would be needed to detect a difference
of 25% in the incidence of CIPNM, which was found to be
37.5% in a previous epidemiological study from our ICU
[ 9 ] .  A n a l y s i s  o f  p a t i e n t  d a t a  w as  b y  i n t e n t i o n  t o  t r e a t.
Patients randomized to the EMS group that did not
finally receive any EMS sessions were not included in the
analysis. The binary logistic regression, with and without
adjustments, was used to compare the development of
CIPNM between the EMS and the control groups. Nor-
mality of distribution was checked by employing Kolm-
ogorof-Smirnof test. Baseline characteristics of
continuous variables of the EMS group and control group
for the whole cohort, those finally evaluated and those
not evaluated were compared by unpaired Student's t-test
or Mann-Whitney U test, in the case of no normal distri-
bution. Qualitative variables at baseline were compared
by chi-squared test. A chi-squared test with Yates' correc-
tion was also employed to compare the number of
patients evaluated with the number of patients not evalu-
ated between the EMS and the control groups. The
Kaplan-Meier method was used to compare the duration
of weaning between patients with and without CIPNM as
well as between patients assigned to the EMS and control
groups. The two groups were compared using the log-
rank test. All continuous variables are presented by mean
± standard deviation (SD) or median and range in case of
no normal distribution. The odds ratio (OR) and the 95%
confidence interval (CI) are also reported in relation to
the binary logistic regression. P values of less than 0.05
were considered statistically significant.
Results
Study population and randomization
Eight hundred and forty-three patients were admitted to
our multidisciplinary ICU during the 22-month study
period and 471 patients fulfilled the exclusion criteria or
had an ICU stay of less than 48 hours. In two patients,
informed consent was not obtained in time for inclusion
in the study and were, therefore, also excluded from the
study. Of the remaining 370 patients, 142 had an
APACHE II admission score of 13 or more and were thus
considered for randomization. Of these patients, 70 were
randomly assigned to the EMS group and 72 to the con-
trol group. Two patients in the EMS group withdrew their
consent. Of the patients enrolled in the EMS group (n =
68), 28 patients died and 11 patients could not be evalu-
ated with the MRC score due to impaired cognitive state.
Five patients in the EMS group were excluded. The rea-
son for exclusion was prolonged use of neuromuscular
blocking agents (n = 3) and no EMS sessions during their
ICU stay (n = 2). Of the patients enrolled in the control
group (n = 72), 22 patients died and 22 patients could not
be evaluated with the MRC score due to impaired cogni-
tive state. Fifty-two patients were finally evaluated; 24 in
the EMS group and 28 in the control group (Figure 1).
Baseline characteristics of patients randomly assigned
to the EMS group or the control group are shown in Table
1. No statistically significant difference was found
between the two groups in any of the variables.
Concerning the 52 patients who were finally evaluated,
no significant difference was found between the EMS andRoutsi et al. Critical Care 2010, 14:R74
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control group in age (mean ± SD (range), 55 ± 20 (23 to
82) vs. 59 ± 21 (19 to 84) years, respectively, P = 0.41),
gender (male/female, 19/5 vs. 22/6 respectively, P = 0.99),
SOFA sore (mean ± SD (range), 8 ± 3 (3 to 13) vs. 8 ± 3 (3
to 16), respectively, P = 0.50) and SAPS III (mean ± SD
(range), 55 ± 11 (40 to 82) vs. 58 ± 14 (34 to 95), respec-
tively, P = 0.46). APACHE II score was statistically signifi-
cant (mean ± SD (range), 16 ± 4 (13 to 25) vs. 19 ± 5 (13 to
31), respectively, P = 0.03).
Concerning the patients not evaluated, no statistically
significant difference was found between EMS and con-
trol group in gender (male/female, 23/16 vs. 27/17,
respectively,  P  = 0.99), APACHE II score (mean ± SD
(range), 19 ± 5 (13 to 35) vs. 18 ± 5 (13 to 36), respectively,
Figure 1 Schediagram of patients admitted to the ICU and the randomization process. APACHE, Acute Physiology and Chronic Health Evalua-
tion; EMS, electrical muscle stimulation.Routsi et al. Critical Care 2010, 14:R74
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Table 1: Baseline characteristics of 140 critically ill patients randomly assigned to the EMS group or the control group 
(mean ± standard deviation)
EMS group
(n = 68)
Control group
(n = 72)
Age, years 61 ± 19 58 ± 18
Gender M/F 46/22 49/23
Severity of illness at ICU admission
APACHE II score 18 ± 4 18 ± 5
SOFA score 9 ± 3 9 ± 3
SAPS III score 61 ± 13 60 ± 14
Diagnostic category at admission
Sepsis/septic shock, n(%) 11 (16.2) 14 (19.4)
Trauma, n(%) 12 (17.6) 14 (19.4)
Post-surgical, n(%) 13 (19.1) 12 (16.7)
Brain injury, n(%) 24 (25.3) 23 (31.9)
Respiratory failure, n(%) 2 (2.9) 4 (5.6)
Other, n(%) 6 (8.8) 5 (6.9)
Comorbidities
Cardiovascular, n(%) 31 (46) 34 (47)
Respiratory disease, n(%) 8 (12) 14 (19)
GI disease, n(%) 3 (4) 2 (3)
Hepatic disease, n(%) 3 (4) 1 (1)
Renal disease, n(%) 7 (10) 9 (13)
Diabetes melitus, n(%) 9 (13) 10 (14)
Hematological disease, n(%) 3 (4) 1 (1)
Other, n(%) 8 (12) 4 (6)
None reported, n(%) 17 (25) 23 (31)
Duration of sedation, days 12 ± 10 12 ± 11
Sepsis/septic shock, n(%) 54 (77) 58 (80)
Aminoglycoside use, days 5 ± 8 8 ± 11
Corticosteroids use, days 6 ± 9 5 ± 8
Neuromuscular blocking agents use, 
days
1 ± 2 3 ± 5
No statistical significant difference is noted between the groups in any of the parameters.
APACHE, Acute Physiology and Chronic Health Evaluation; EMS, electrical muscle stimulation; F, female; GI, gastrointestinal; M, male; SAPS, 
Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment.Routsi et al. Critical Care 2010, 14:R74
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P = 0.13), SOFA score (mean ± SD (range), 9 ± 4 (4 to 21)
vs. 9 ± 3 (4 to 14), respectively, P = 0.82) and SAPS III
(mean ± SD (range), 65 ± 13 (43 to 99) and 61 ± 14 (33 to
97), respectively, P = 0.16). Age was higher in the EMS
group (mean ± SD (range), 65 ± 17 (22 to 85) vs. 58 ± 16
(20 to 89) years, respectively, P = 0.03).
No difference was observed between the number of
patients evaluated with the number of patients not evalu-
ated between the EMS and the control group (P > 0.99).
Diagnosis of critical illness polyneuromyopathy
CIPNM was diagnosed in 3 patients in the EMS group as
compared with 11 patients in the control group (OR =
0.22, 95% CI = 0.05 to 0.92, P = 0.04; Table 2). The inci-
dence of CIPNM was also lower in the EMS group when
comparison was adjusted for age and APACHE II score
(OR = 0.22, 95% CI = 0.05 to 1.02, P = 0.05), variables for
which a significant between-group difference was found
in patients finally not evaluated and evaluated, respec-
tively, according to the intention to treat approach. The
MRC score was statistically significantly higher in
patients assigned to the EMS group as compared with the
control group (median = 58, range = 33 to 60 vs median =
52, range = 2 to 60, P = 0.04; Figure 2).
Weaning from mechanical ventilation
The median short-term weaning period of critically ill
patients was 2 (range = 0 to 99) days and the median
long-term weaning period was 3 (range = 0 to 99) days.
Four patients did not need mechanical ventilation during
their ICU stay and one patient was not able to be weaned
from the ventilator.
Patients that developed CIPNM had a longer short-
term weaning period as compared with patients that did
not develop CIPNM (median (range), 3 (0 to 44) vs. 1 (0
to 10) days, respectively, P = 0.003). Patients that devel-
oped CIPNM had a prolonged long-term weaning period
compared with those without CIPNM (median (range),
12 (0 to 44) vs. 1 (0 to 10) days, respectively, P = 0.0001).
The duration of mechanical ventilation was shorter for
patients assigned to the EMS group compared with
patients in the control group (median (range), 7 (2 to 41)
vs. 10 (1 to 62), days, respectively), however, this differ-
ence was barely significant (log rank test, P = 0.07). The
short-term weaning period was significantly shorter in
patients assigned to the EMS group as compared with
patients assigned to the control group (median (range), 1
(0 to 10) vs. 3 (0 to 44) days, respectively, log rank test, P =
0.003). The long-term weaning period was significantly
shorter in patients assigned to the EMS group compared
with those in the control group (median (range), 1 (0 to
16) vs. 4 (0 to 44) days, respectively, log rank test, P =
0.003). Finally, the number of days off the ventilator were
significantly less in patients assigned to the EMS group
compared with patients in the control group (median
(range), 4 (0 to 16) vs. 6 (0 to 41) days, respectively, log
rank test, P = 0.003; Figure 3).
Figure 2 Difference in the MRC scale for muscle strength be-
tween patients assigned to the EMS group as compared with pa-
tients assigned to the control group (mean ± 2 standard errors). P 
= 0.04. EMS, electrical muscle stimulation; MRC, Medical Research 
Council.
Table 2: Diagnosis of CIPNM in patients assigned to the EMS group as compared with patients assigned to the control 
group (P = 0.04)
EMS group (n) (%) Control group (n)(%) Total
CIPNM 3 (12.5) 11 (39.3) 14
No CIPNM 21 (87.5) 17 (60.7) 38
Total 24 28 52
CIPNM, critical illness polyneuromyopathy; EMS, electrical muscle stimulation.Routsi et al. Critical Care 2010, 14:R74
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Five patients (four in the control group and one in the
EMS group) were reintubated.
ICU length of stay
Patients that developed CIPNM had a longer ICU stay
compared with patients that did not develop CIPNM
(mean (range), 25 (4 to 92) vs. 11 (3 to 49), days, respec-
tively, log rank test, P = 0.01). The duration of ICU stay,
although shorter in patients assigned to the EMS group
compared with those in the control group, was not found
to be significantly different (mean (range), 14 (4 to 62) vs.
22 (2 to 92), days, respectively, log rank test, P = 0.11; Fig-
ure 4).
Discussion
The main finding of our study is that daily, 55-minute
EMS sessions prevented the development of CIPNM in
critically ill patients. Furthermore, EMS treatment was
associated with a shorter duration of weaning from
mechanical ventilation.
For the prevention of CIPNM, avoidance of known risk
factors, including hyperglycemia, is the only preventive
measure proposed so far [22]. To our knowledge, this is
the first randomized parallel intervention study to sug-
gest that EMS can prevent the development of CIPNM in
critically ill patients and preserve the muscle strength as
assessed with the MRC score, thus potentially providing a
preventive tool for this condition. The incidence of
CIPNM was lower in the EMS group even after compari-
son was adjusted for variables for which a significant
between group difference was found in baseline statistics
in the subgroup of patients finally evaluated and not eval-
uated.
EMS has been extensively used as an alternative form of
exercise in patients with severe COPD [12,13,23] and
CHF [11]. In these patients who could not perform any
form of active exercise due to respiratory or cardiac insuf-
ficiency, EMS was well tolerated and resulted in an
improvement of muscle performance such as maximum
voluntary contraction [13], muscle strength and endur-
ance [12], and additionally, in an improvement of exercise
capacity [11,13] and quality of life [11,23]. In a recent
study involving bed-bound patients with COPD receiving
mechanical ventilation after an ICU stay, EMS caused an
increase in muscle strength, as assessed with the MRC
scale, and reduced the number of days for transfer from
bed to chair [23]. In a previous study by our group, daily
EMS sessions implemented from the second day of ICU
admission, to a large extent preserved the muscle mass of
critically ill patients as assessed with ultrasonography
[24]. Specifically, after eight days of daily EMS sessions on
lower extremities (quadriceps and peroneus longus mus-
cles) the decrease in muscle mass of the quadriceps mus-
cle as assessed with ultrasonography was significantly less
in the EMS group. In the present study, EMS was imple-
mented in all patients assigned to the EMS group from
the second day after admission with the only contraindi-
cation being the use of neuromuscular blocking agents.
Three patients, although initially included in the study,
were finally excluded due to prolonged use of neuromus-
cular blocking agents that did not allow the implementa-
tion of EMS. The rationale behind the choice of
stimulated muscles was based on accessibility and func-
tional significance for CIPNM. The daily EMS sessions
were aimed at achieving the maximum possible effect.
EMS was well tolerated and no side effects occurred dur-
ing the sessions as has been previously described [15,24].
As it does not require the patient's cooperation it was
easily applicable from the day of admission.
The pathophysiological mechanisms involved in this
finding could be that EMS, as an alternative form of exer-
cise, acts as an anabolic stimulus to the muscle reversing
the catabolic effects of critical illness and immobilization.
In an early study involving critically ill patients it has
been shown that EMS has beneficial effects on muscle
metabolism [25]. Addressing the pathophysiological
bases of the effects of EMS on the main determinants of
work capacity, Pérez and colleagues showed that EMS
implementation in healthy young men improved oxygen
uptake (VO2) kinetics and work efficiency [26]. Also,
EMS applied to the lower limbs of critically ill patients
induced an acute systemic effect on the microcirculation
of the thenar as assessed with the near infrared spectros-
copy technique, indicating the presence of factors
induced by EMS, that act in a systemic way [15]. It is pos-
sible that molecules such as cytokines, produced at the
loci of EMS and distributed via the circulation could be
responsible for the systemic effect of EMS in preventing
CIPNM observed in our study. Several cytokine levels,
primarily IL-6 have been shown to increase after exercise
[27,28]. IL-6 mRNA has been shown to increase after an
EMS session in rat skeletal muscles [29,30]. Moreover, it
is possible that central command and activation of
metabo-reflex and/or ergo-reflex during EMS may
increase sympathetic discharge and contribute to changes
in heart rate, systolic blood pressure, blood volume and
cardiac output, and therefore affect the skeletal muscle
metabolism in a systemic way [31,32]. Finally, a bioener-
getic pathway may be activated during EMS contributing
to an improvement in mitochondrial function of the skel-
etal muscle [33]. Current approaches for CIPNM diagno-
sis comprise physical motor examination (e.g. with the
MRC score for muscle strength) and electrophysiological
investigations. The MRC score assessment depends on
patient's cooperation and cannot be performed in
patients who are not fully awake. Under these circum-
stances, CIPNM diagnosis relies on electrophysiologicRoutsi et al. Critical Care 2010, 14:R74
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studies [10,34]. However, several limitations exist and
risks and costs of this testing should be taken into
account. Conventional electrodiagnostic techniques
often provide non-specific results or are hampered by
local conditions (edema, multiple electrical devices) that
prevent adequate disease classification [1]. Additionally,
neurophysiologic testing results failed to predict duration
of ICU stay or mechanical ventilation. Our main concern
was to evaluate if EMS could affect the development of
muscle weakness in our patients. Therefore physical
examination has been selected as the primary determi-
nant of CIPNM [4,20].
A number of studies have evaluated the role of early
mobilization and/or physiotherapy in critically ill patients
[35-40]. These studies involved passive limb mobilization
[35-37], limb [35-38] and respiratory [37,39] muscle
training, and bed cycling [40]. Although favorable results
in terms of muscle strength [36-38], mobilization [37],
six-minute walking distance [40] and ICU and hospital
length of stay [35,37] have been shown, the development
of CIPNM was not evaluated. It is also noteworthy that
limb and respiratory muscle training require patient
cooperation and could not be performed immediately
after admission for the majority of critically ill patients, as
Figure 3 Kaplan-Meier curves of the probability of remaining under mechanical ventilation after the onset of weaning. (a) Duration of me-
chanical ventilation (log rank test, P = 0.075). (b) Days off mechanical ventilation (log rank test, P = 0.003). (c) Weaning period (short-term): no need for 
mechanical ventilation for the next 48 hours (log rank test, P = 0.003). (d) Weaning period (long-term): no need for mechanical ventilation until ICU 
discharge (log rank test, P = 0.003) for patients in the electrical muscle stimulation (EMS) group as compared with those in the control group.Routsi et al. Critical Care 2010, 14:R74
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opposed to EMS. Finally, intensive insulin therapy has
been reported as a possible preventive tool for CIPNM
[22].
A second finding from this study is that patients that
developed CIPNM had prolonged duration of weaning
process and prolonged ICU stay as compared with
patients that did not develop CIPNM. This finding is con-
sistent with the findings of recent studies that reported
prolonged duration of weaning and prolonged ICU stay
in critically ill patients with CIPNM as compared with
patients without CIPNM [2,41].
Interestingly, patients assigned to the EMS group had a
shorter duration of weaning as compared with patients
assigned to the control group, which is further indication
of the presence of a relation between limb and respiratory
muscle weakness. As has been already mentioned an
acute systemic effect has been reported after one EMS
session [15]. It is possible that the reported systemic
effect of EMS acts as an anabolic stimulus to the respira-
tory muscles as well. Generally speaking the procatabolic
cytokine environment that characterizes disease states
associated with inflammation and the critically ill, due to
excessive localized elaboration of proinflammatory
cytokines [42] may be altered by EMS. A possible role is
suggested for IL-6, which reduces insulin-like growth fac-
tor 1 production, providing a major mechanism by which
chronic inflammation inhibits hormonal anabolic action
and affects growth [43]. Exercise training reduces IL-6
production as well as the magnitude of the acute exercise
IL-6 response and a decreased plasma IL-6 concentra-
tion, not only in response to exercise but also at rest,
appears to characterize a normal exercise adaptation [44].
The same mechanism, affecting muscle protein turnover,
could hold true for EMS implementation. The shorter
duration of weaning in patients assigned to the EMS
group implies a beneficial effect of EMS on respiratory
muscle function and reinforces the clinical significance of
this study.
Clinical implication
This is the first randomized parallel intervention trial to
suggest that EMS of lower extremities can prevent the
development of CIPNM in critically ill ICU patients.
Daily EMS sessions prevented the development of
CIPNM, preserved the muscle strength and shortened
the duration of weaning and ICU stay in critically ill
patients. EMS is an easily applicable, well-tolerated form
of exercise that does not require patient cooperation, can
be applied in any muscle group and can be implemented
immediately after ICU admission. In our study, daily EMS
sessions prevented CIPNM and shortened the duration of
weaning from the ventilator, thus contributing to
decreased morbidity and shorter ICU stay.
Further studies are needed to define which patients
would benefit most from this intervention and to explore
the EMS characteristics (current characteristics and mus-
cle groups) that are most appropriate for preventing
CIPNM.
Limitations
The main limitation of our study is the relatively small
number of critically ill patients that were able to be evalu-
Figure 4 Kaplan-Meier curves comparing the ICU length of stay in patients with and without critical illness polyneuromyopathy (CIPNM; 
log-rank test, P = 0.01) and between patients assigned to the electrical muscle stimulation group as compared with patients assigned to 
the control group (log-rank test, P = 0.11).Routsi et al. Critical Care 2010, 14:R74
http://ccforum.com/content/14/2/R74
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ated for the development of CIPNM. In addition, we did
not use sham-EMS sessions in patients assigned to the
control group. Furthermore, the investigators performing
the MRC scale were not blinded to patients treatment
assignment (EMS or control). However, they were
unaware of each others' assessments. In addition, the
effect of EMS was assessed on muscle strength, but not
on muscle function or ability to perform activities of daily
living because our study was conducted in the ICU set-
ting. Also, an electrophysiological evaluation was not
performed, which would have assisted in the evaluation
of patients who did not regain adequate cognitive func-
tion in order to perform the MRC scale. Finally, the high
mortality rate due to the increased illness severity should
be noted.
Conclusions
CIPNM is a common complication of critical illness asso-
ciated with muscle weakness and prolonged duration of
weaning and ICU stay. This is the first randomized con-
trolled study suggesting that daily EMS sessions can pre-
vent the development of CIPNM in critically ill patients
and also result in shorter duration of weaning, thus
potentially providing a preventive tool for this condition.
Key messages
• CIPNM is a common complication of critical illness
presenting with muscle weakness, areflexia, pro-
longed duration of weaning from mechanical ventila-
tion and prolonged ICU and hospital stay.
• Searching for the potentially reversible risk factors
and subsequent adjustment of therapy are so far
advocated as preventive measures to decrease the risk
of CIPNM.
•  EM S  i s  a  f o r m  o f  e x e r c i s e  t h a t  d o e s  n o t  r e q u i r e
patient cooperation and has been used in patients
with severe COPD and CHF. Previous studies from
our group have suggested that EMS has an acute sys-
temic effect and preserves the muscle mass of criti-
cally ill patients.
• This is the first randomized parallel intervention
study to show that EMS can prevent the development
of CIPNM in critically ill patients, thus effectively
providing a preventive tool for this condition.
• EMS sessions also resulted in significantly shorter
duration of weaning period from the ventilator.
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